Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
JPMorgan: Market’s initial reaction to spot Ethereum ETF may be negative

JPMorgan: Market’s initial reaction to spot Ethereum ETF may be negative

Bitget2024/06/02 01:12

Golden Finance reported that the U.S. Securities and Exchange Commission (SEC) approved a spot Ethereum exchange-traded fund (ETF), raising expectations of significant inflows. However, JPMorgan warned that these hopes may be overly optimistic compared to spot Bitcoin ETFs. JPMorgan analysts outlined several reasons for their cautious outlook. They detailed Bitcoin's "first-mover advantage" and the recent halving event as important demand catalysts for Bitcoin ETFs, which Ethereum lacks. Noting that Ethereum's proof-of-stake mechanism does not provide a similar demand boost, the analysts stressed that the Bitcoin halving event "acted as an additional demand catalyst for spot Bitcoin ETFs."

In addition, they pointed out that the exclusion of staking in the spot Ethereum ETF application makes these funds "less attractive than platforms that offer staking returns." Bitcoin's position as a competitor to gold in portfolio allocation further increases its demand for Ethereum, which is primarily seen as an application token. In addition, JPMorgan detailed that Ethereum's lower liquidity makes it less attractive to hedge funds and quantitative funds.

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Chinese 3D vision AI startup Sensing4D AI submits IPO application to US stock market: plans to raise $35 million and advance embodied intelligence simulation.

Sensing4D AI plans to go public on Nasdaq, aiming to raise $35 million, with a primary focus on 3D reconstruction and embodied intelligence simulation. The company's annual revenue is $29 million.

智通财经•2026/10/23 08:57

Rezera (RZRA.US) submits IPO application: Oral NLRP3 inhibitor pipeline progresses, Phase 3 PAD trial scheduled to begin in 2027

Rezera plans to go public on Nasdaq to raise 100 millions USD. Its oral NLRP3 inhibitor will initiate a Phase III trial for PAD, with data expected in 2028.

智通财经•2026/10/23 08:32